Fudan University

This phase 2 trial tests a combination of two immune-boosting drugs (iparomlimab and tovorilimab) plus bevacizumab and standard chemotherapy as a first treatment for advanced mesothelioma. The study will enroll 37 adults who have not had prior therapy. Researchers will measure ho…

This phase II trial tests a combination of targeted drugs and hormone therapy given before surgery for a specific type of breast cancer (ER-positive, HER2-positive). The goal is to shrink tumors without using standard chemotherapy. The study will enroll 42 women and measure how m…

This phase II trial tests two drugs—anlotinib and benmelstobart—as a second-line treatment for people with advanced or metastatic differentiated thyroid cancer that has not responded to first-line therapy. The study will enroll 23 participants and measure how many see their tumor…

This phase 2 trial is testing a combination of an experimental immunotherapy (epalrotokewali) with chemotherapy (eribulin), a targeted drug (anlotinib), and radiation for people with advanced soft tissue sarcoma that has worsened after initial treatment. The study will enroll 46 …

This phase 2 trial tests a new immunotherapy combination (iparomlimab and tovorilimab) plus standard chemotherapy and bevacizumab before surgery in 36 women with advanced ovarian cancer. The main goal is to see how many patients achieve complete tumor removal (R0 resection). The …

This study tests whether a new drug combination (RC48 plus chemotherapy) works better than standard treatments for people with HER2-positive advanced breast cancer whose disease has worsened after prior therapy with a topoisomerase I inhibitor antibody-drug conjugate. About 268 w…

This Phase 2 trial tests a new combination of drugs—paclitaxel polymer micelles, trastuzumab, pertuzumab, and adebelimab—as a first treatment for advanced HER2-positive breast cancer. About 140 participants will be randomly assigned to receive either this new combo or the standar…

This study tests whether Huaier granules, a traditional Chinese medicine, can help lower certain tumor markers (CEA, CA125, CA153) in people with early-stage breast cancer. About 232 participants will be randomly assigned to receive the granules or not, and researchers will compa…

This study tests whether a chemotherapy-free treatment using the targeted drug Dalpiciclib (a CDK4/6 inhibitor) plus hormone therapy works as well as standard chemotherapy for women with small, high-risk, hormone-receptor-positive breast cancer. About 2,288 participants will be r…

This study tests whether an artificial intelligence (AI) model can choose the best combination of targeted drugs for women with HER2-positive breast cancer before surgery. About 280 women with early or locally advanced breast cancer will be randomly assigned to either AI-guided t…

This study looks at whether women with a certain type of early-stage breast cancer can safely take hormone therapy for only 2 to 3 years instead of the usual longer period. About 2,900 participants will be randomly assigned to either the shorter or standard treatment. The goal is…

This study tests a new approach for people with liver cancer that is too advanced for standard transplant criteria but can still be surgically removed. Participants will receive a liver-directed treatment (TACE) combined with an immunotherapy drug (QL1706) before surgery, and con…

This study tests a combination of three drugs (sintilimab, bevacizumab, and chemotherapy) in people with a rare and aggressive type of stomach cancer that produces a protein called AFP. The goal is to shrink the tumors enough so they can be surgically removed. About 46 adults wit…

This study tests a drug called Vebreltinib given for 8 weeks before surgery in 30 people with a specific type of lung cancer (stage IIA-IIIB NSCLC with a MET gene change). The goal is to see if the drug can shrink tumors enough to improve surgery results. Participants take pills …

This study tests two different treatment sequences for people with high-risk locally advanced rectal cancer. One group gets standard long-course chemoradiation followed by chemotherapy, while the other gets short-course radiation followed by a combination of chemotherapy and an i…

This phase 2 study tests whether the drug hetrombopag can prevent dangerously low platelet counts caused by chemotherapy in breast cancer patients at high risk. About 126 participants will be split into three groups: one getting no preventive drug, one taking hetrombopag continuo…

This phase II trial tests an immunotherapy drug called SHR-1701 combined with chemotherapy and radiation for people with stage III non-small cell lung cancer that cannot be removed by surgery. The study will compare giving SHR-1701 before or after standard chemoradiation. The mai…

This phase II trial tests a combination of two drugs—sacituzumab tirumotecan and furmonertinib—in 45 people with advanced EGFR-mutant non-small cell lung cancer whose first targeted therapy stopped working. The study measures how many patients respond to treatment and how long th…

This study looks at whether taking leucogen (a drug that raises white blood cell counts) from the start can prevent low white blood cells in people with RET fusion-positive non-small cell lung cancer who are taking pralsetinib. About 25 people who have not had prior treatment wil…

This Phase 2 trial tests whether adding all-trans retinoic acid (a vitamin A derivative) to standard VAC chemotherapy improves outcomes for 106 people aged 14-60 with intermediate-to-high-risk rhabdomyosarcoma, a rare muscle cancer. Participants will receive the drug combo in 21-…

This Phase 2 trial is testing whether the combination of envafolimab (an immunotherapy) and lenvatinib (a targeted therapy) can shrink liver tumors in people with clear cell kidney cancer that has spread to the liver. The study will enroll 30 adults who have not received prior tr…

This study tests whether combining trastuzumab with either pyrotinib or dalpiciclib plus hormone therapy can help control advanced HER2-positive breast cancer after initial treatment. About 288 women with cancer that has spread or cannot be removed will receive these maintenance …

This study tests whether a combination of targeted drugs and hormone therapy can replace chemotherapy for people with a specific type of early-stage breast cancer (HR-positive, HER2-positive, no lymph node spread). About 1,500 participants will receive either the standard chemo p…

This study tests a new two-drug combination for people with a certain type of advanced colorectal cancer that has not responded to prior treatments. About 31 adults will receive the drugs to see if tumors shrink and how long that lasts. The goal is to find a better option for lat…

This study tests whether a single, low dose of radiation to all visible tumors can help immunotherapy start working again in people with advanced esophageal cancer that has stopped responding to standard chemo-immunotherapy. About 32 adults will receive the radiation and then con…

This study tests a new approach for people with high-risk locally advanced rectal cancer. It combines a shorter course of radiation with chemotherapy and an immunotherapy drug (serplulimab). The goal is to see if this combination leads to more complete remissions compared to the …

This study tests whether adding branched-chain amino acids (BCAAs) to a standard two-drug therapy (lenvatinib plus pembrolizumab) helps adults with advanced liver cancer that cannot be removed by surgery. About 234 participants will be randomly assigned to receive the standard th…

This study tests whether adding surgery and targeted radiation to a new hormone drug (rezvilutamide) can help men whose prostate cancer has spread to a few spots (oligometastatic). About 300 men will be split into three groups: one gets the drug alone, another gets the drug plus …

This study tests whether adding the drug disitamab vedotin to standard BCG therapy can help keep high-risk, early-stage bladder cancer from returning. It includes 182 adults whose cancer has been surgically removed but is at high risk of coming back. Participants will receive eit…

This study tests a treatment called multimodal thermal therapy (MTT) that uses both freezing and heating to destroy liver tumors. The goal is to see if this approach can control the cancer and also trigger the body's immune system to fight it. About 120 adults with liver cancer o…

This study tests three ways of giving the immunotherapy drug toripalimab to people with early-stage lung cancer that can be removed by surgery. The goal is to see which timing works best: before surgery only, after surgery only, or both before and after. About 759 adults with sta…

This study tests two drugs together—pucotenlimab and becotatug vedotin—for people with advanced cutaneous squamous cell carcinoma that cannot be removed by surgery. The goal is to see if the combination shrinks tumors better than current treatments. About 38 participants will rec…

This study looks at young women (ages 18-45) with hormone-sensitive breast cancer who are already on a 3-month hormone injection to suppress ovarian function. Researchers want to see if switching to a monthly injection keeps estrogen levels lower and more stable. About 100 partic…

This study tests a combination of two experimental drugs (iparomlimab and tuvoraleimab) plus standard chemotherapy for people with advanced acral or mucosal melanoma, rare and aggressive skin cancers. About 48 adults who have had little or no prior treatment will receive the ther…

This study tests whether giving a daily probiotic mixture for 6 months can improve brain development in preterm infants who received antibiotics after birth. Researchers will enroll 116 babies and measure their developmental scores, gut bacteria changes, and inflammation markers.…

This study tests whether taking the oral drug everolimus after standard chemotherapy can help prevent breast cancer from coming back in people with a specific subtype of triple-negative breast cancer called LAR. The trial will enroll 904 women who have had surgery for early-stage…

This study tests a new combined treatment system for liver cancer that uses heat to destroy tumors. It will include 20 adults with primary or metastatic liver cancer who cannot have surgery. The goal is to see if the treatment is safe, how well it works at shrinking tumors, and h…

This study tests whether adding famitinib to SHR-A1811 works better than SHR-A1811 alone for people with a certain type of advanced breast cancer (HR+/HER2-) that no longer responds to CDK4/6 inhibitors. About 248 women aged 18-70 will take part. The goal is to see if the combina…

This study tests whether a new drug, sacituzumab tirumotecan (Sac-TMT), followed by standard chemotherapy (capecitabine), works better than capecitabine alone to keep early-stage, high-risk triple-negative breast cancer from returning. About 420 women without BRCA gene mutations …

This study looks at whether adding diabetes medication to standard chemotherapy can help people with metastatic pancreatic cancer and diabetes live longer. About 210 adults with both conditions will receive either chemotherapy alone or chemotherapy plus active diabetes treatment.…

This study tests whether taking two drugs (imlunestrant and abemaciclib) before surgery can shrink tumors in people with a common type of breast cancer (ER+/HER2-). About 189 women aged 18-75 with early-stage breast cancer will join. The treatment is guided by a marker called Ki6…

This study tests whether a three-drug combination can help people with triple-negative breast cancer whose tumors stopped responding to immunotherapy. About 46 women will receive cromolyn, TQB2102, and panpulimab to see if tumors shrink or stop growing. The goal is to control the…

This study looks at men with advanced prostate cancer that has spread to other parts of the body. After 6 months of hormone therapy, those whose scans show the cancer is well-controlled may either continue hormone therapy alone or also have their prostate removed. The goal is to …

This study tests whether adding a traditional Chinese herbal formula (Qiqi Shengmai) to standard care can improve blood flow in the brains of people with moyamoya disease. About 66 adults aged 18 to 80 will receive either the herbal formula or a placebo for a set period. The goal…

This study looks at two powerful drugs, sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd), for people with a certain type of advanced breast cancer (HER2-low/TROP2-high). The goal is to find out which drug works best when given first and how to switch if the first sto…

This study tests a new way to give radiation for advanced non-small cell lung cancer. The approach uses a mix of high and low radiation doses along with chemotherapy and immunotherapy before and after radiation. The goal is to shrink tumors more quickly and reduce the risk of lun…

This study tests a new approach for people with HER2-negative breast cancer that has spread to the liver and hasn't responded to prior treatments. It combines a special heat therapy (multi-mode thermal therapy) with immunotherapy to see if it can slow or shrink tumors. About 30 p…

This study tests a personalized approach for people with advanced esophageal cancer that cannot be removed by surgery. Doctors will use MRI scans to guide a custom combination of chemotherapy, radiation, and immunotherapy. The goal is to see if this tailored treatment can help ke…

This study tests a new drug, QLC5513, alone or with another drug (QL1706) in 60 women with advanced triple-negative breast cancer that has worsened after at least one prior treatment. The goal is to see if these drugs can shrink tumors or slow the cancer's growth. Participants wi…

This study looks at how well the drug Toripalimab works as the first treatment for people with extensive-stage small cell lung cancer, a fast-growing lung cancer that has spread. Researchers will track 1,200 patients in China to see how long the cancer stays under control and how…

This study tests whether using a 3D-PTA drug sensitivity test to choose chemotherapy after surgery works better than standard chemo for people with stage II/III bile duct cancer. About 98 adults who had their tumor removed will be randomly assigned to either personalized chemo or…

This study tests different drug combinations before surgery for people with locally advanced colorectal cancer. The treatment is chosen based on the tumor's genetic and molecular features. The goal is to see if this personalized approach can eliminate the cancer before surgery, a…

This study tests whether a new combination of immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy works better than another immunotherapy plus chemotherapy for people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer. About 104 adults will…

This study tests whether adding bevacizumab to trastuzumab deruxtecan (T-DXd) helps control HER2-low breast cancer that has spread to the brain. About 140 adults with this condition will receive either T-DXd alone or T-DXd plus bevacizumab. The goal is to see which approach delay…

This study tests three treatment plans for people with a specific type of colorectal cancer (MSI-H/dMMR) that has spread locally but not to distant organs. The goal is to see if combining two immunotherapy drugs, or adding radiation to one immunotherapy drug, works better than on…

This study tests whether adding neratinib to the standard drug trastuzumab deruxtecan works better for HER2-positive breast cancer that has spread to the brain. About 202 women aged 18-70 will be randomly assigned to get the combination or the standard drug alone. The main goal i…

This study tests a new combination of two drugs (becotatug vedotin and pucotenlimab) in 20 adults with advanced penile cancer that has spread and is EGFR-positive. Participants must have failed or be unable to tolerate chemotherapy. The goal is to see if the treatment can shrink …

This study tests whether a new drug combination (fruquintinib plus chemotherapy) works better than the current standard (bevacizumab plus chemotherapy) for people with a specific type of advanced colorectal cancer that has a RAS mutation. About 224 adults aged 18 to 75 will be ra…

This study tests whether adding fluzoparib (a daily pill for one year) to standard treatment can help prevent breast cancer from returning in women with early-stage breast cancer who have inherited changes in HRR genes. About 334 women aged 18-75 will be randomly assigned to rece…

This study looks at whether a combination of ribociclib (a targeted drug) and hormone therapy can be as effective as chemotherapy followed by the same combo for people with a common type of early breast cancer (HR+/HER2-). Only patients whose blood tests show no signs of cancer D…

This study will see if artificial intelligence can find and diagnose kidney tumors and cysts using standard CT scans that don't require dye. Researchers will analyze scans from 10,000 people to build a smart system that tells cysts from benign and malignant growths. The goal is t…

This study tests whether an AI chatbot can help women aged 15 to 26 in China feel more confident about getting the HPV vaccine. About 1800 participants will be split into two groups: one gets access to the chatbot, the other does not. Researchers will compare vaccination rates an…

This study tests whether finding and treating high-risk types of H. pylori bacteria can prevent stomach cancer. About 4,800 adults aged 40 and older will be screened for these bacteria and then receive treatment to eliminate them. Researchers will track how many people develop st…

This study tests whether an AI-powered chatbot and smart reminders can encourage more high-risk adults aged 45 to 74 to get a colonoscopy, the best way to detect colorectal cancer early. About 1,680 participants will be split into two groups: one gets usual care, the other also g…

This study tests whether adding Huaier Granule to standard care can reduce proteinuria (excess protein in urine) in breast cancer patients who developed it as a side effect of immunotherapy or anti-angiogenic therapy. About 120 women will be randomly assigned to receive either st…

This study tests whether Huaier Granules, a traditional Chinese medicine, can treat proteinuria (excess protein in urine) caused by two common lung cancer drugs, Bevacizumab and Anlotinib. About 40 adult lung cancer patients with mild to moderate proteinuria will take the granule…

This study tests whether adding Yueju Pill, a traditional Chinese medicine, to standard cancer treatment can improve quality of life for people with advanced biliary tract cancer. About 210 adults with this rare cancer will receive either Yueju Pill or a placebo alongside their u…

This study tests whether adding a transparent cap to the tip of a colonoscope helps doctors find more polyps (adenomas) in the lower part of the colon during a second look. About 614 adults aged 45 to 75 will be randomly assigned to get either a standard second exam or one with t…

This study looks at whether stopping GLP-1 receptor agonists (like Ozempic or Wegovy) for two weeks before an upper endoscopy lowers the chance of food staying in the stomach. Researchers will review medical records from over 16,000 people to compare those who paused the drug wit…

This study will observe 460 diabetic patients who take semaglutide to see if those with nerve damage (neuropathy) are more likely to develop gastric retention, where the stomach doesn't empty properly. Researchers will compare patients with and without neuropathy during routine e…

This study aims to develop an artificial intelligence system that can more accurately assess how clean the bowel is during a colonoscopy. Current AI methods assume the scope moves at a constant speed, which isn't realistic. By using a positioning system that tracks the scope's ac…

This observational study will enroll 158 adults with advanced or recurrent esophageal cancer who plan to receive PD-1 inhibitor immunotherapy. Researchers want to see if a high level of a specific immune cell type (precursor exhausted T cells, or Tpex) in cancer-free lymph nodes …

This study tests whether special PET/MRI scans using different tracers can predict how well breast cancer treatments work. Researchers will scan 300 women before and after two cycles of therapy. The goal is to find which scans best signal treatment success, helping future patient…

This study looks at whether stopping the diabetes drug semaglutide for one week before an upper endoscopy reduces the chance of food or liquid staying in the stomach, which can make the procedure riskier and harder to see clearly. About 418 adults who either take semaglutide long…

This study looks back at medical records of 150 people aged 90 or older who had elective inguinal hernia repair with mesh. The goal is to understand how often serious complications happen and what factors might increase risk. Researchers will collect data from before, during, and…

This study looks at how three different anesthetics change brain activity and connectivity when people are unconscious. Researchers will monitor the brain waves of 120 adults having non-cardiac surgery to find patterns that show when someone is truly unaware. The goal is to devel…

This study tests whether artificial intelligence (AI) can help more high-risk adults aged 40 to 64 get colonoscopies to screen for colorectal cancer. About 400 participants will be split into two groups: one gets usual care, the other gets AI-assisted support from doctors and nur…

This study observes 400 adults with advanced HER2-negative breast cancer who have already received antibody-drug conjugates. Researchers will track how long patients stay cancer-free or alive after starting eribulin-based therapy. The goal is to understand real-world treatment ou…

This study looks at whether a simple blood test can help doctors decide the best treatment after surgery for stomach or gastroesophageal junction cancer. About 32 people with stage III or IVA cancer will give blood samples before and after surgery to check for tumor DNA. The goal…

This study looks at 100 people who needed surgery for a mesh infection after hernia repair. It compares removing all the mesh versus removing only part of it, to see which approach leads to fewer hernia comebacks and fewer repeat infections. The goal is to help doctors choose the…

This observational study aims to develop a system that combines genetic and clinical data to predict which patients with colorectal cancer that has spread to the liver are at high risk of the cancer coming back after surgery. Researchers will study 200 adults aged 18-75 who have …

This observational study aims to see if a specific type of immune cell (Tpex) found in cancer-free lymph nodes can predict whether esophageal cancer will completely respond to immunotherapy given before surgery. Researchers will study 88 people with esophageal cancer who are sche…

This study enrolls 30 people with cancer that has spread (metastasized). Researchers take a sample of the tumor and analyze its RNA to see if they can predict where the cancer originally started. No treatment is given; the goal is to see how accurate the RNA test is at identifyin…

This study will follow 3000 adults aged 40 and older who are at high risk for stomach cancer. Participants will provide a stool sample and have a normal stomach exam at the start. Researchers will track who develops stomach cancer over 10 years to see if a simple stool test can p…